Biomx Inc
PHGE
查看詳細走勢圖
1.930USD
-0.070-3.50%
收盤 12/26, 16:00（美東）報價延遲15分鐘
2.72M總市值
虧損本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
-3.50%
5天
+2.66%
1月
-66.61%
6月
-78.79%
今年開始到現在
-86.09%
1年
-81.32%
查看詳細走勢圖
TradingKey Biomx Inc股票評分
單位: USD 更新時間: 2025-10-27操作建議
當前估值合理，機構持股佔比非常高，近一個月多位分析師給出公司評級為買入。最高目標價max_target_price。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Biomx Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
2
分析師
買入
評級
165.000
目標均價
+4961.35%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
Biomx Inc亮點
亮點風險
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
估值低估
公司最新PE估值-18.64，處於3年歷史低位
機構減倉
最新機構持股11.81M股，環比減少24.87%
活躍度增加
近期活躍度增加，過去20天平均換手率2.96
Biomx Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Biomx Inc簡介
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
公司代碼PHGE
公司Biomx Inc
CEOSolomon (Jonathan Eitan)
網址https://www.biomx.com/
常見問題
Biomx Inc(PHGE)的當前股價是多少？
Biomx Inc(PHGE)的當前股價是 1.930。
Biomx Inc 的股票代碼是什麼？
Biomx Inc的股票代碼是PHGE。
Biomx Inc股票的52週最高點是多少？
Biomx Inc股票的52週最高點是22.057。
Biomx Inc股票的52週最低點是多少？
Biomx Inc股票的52週最低點是1.500。
Biomx Inc的市值是多少？
Biomx Inc的市值是2.72M。
Biomx Inc的淨利潤是多少？
Biomx Inc的淨利潤為-17.73M。
現在Biomx Inc(PHGE)的股票是買入、持有還是賣出？
根據分析師評級，Biomx Inc(PHGE)的總體評級為買入，目標價格為165.000。
Biomx Inc(PHGE)股票的每股收益（EPS TTM）是多少
Biomx Inc(PHGE)股票的每股收益（EPS TTM）是-37.042。
相關品種
+0.05%
-0.07%
+0.08%
+0.49%
+0.23%
+0.38%
-0.31%
-0.30%
-0.77%
+0.30%
+0.23%
-0.02%
-0.07%
+0.24%
+0.26%
+0.30%
+0.16%
0.00%
+0.58%
-0.02%
